Trials / Unknown
UnknownNCT03732508
SHR-1316 in Combination With Chemotherapy in Patients With Esophageal Squamous Cell Cancer
SHR-1316, a Novel Anti-PD-L1 Antibody, in Combination With Irinotecan Liposome and Fluorouracil in Patients With Esophageal Squamous Cell Cancer: a Phase II Study
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the progression-free survival (PFS) of Chemotherapy combined with SHR-1316 in patients with advanced esophageal squamous cell cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Irinotecan liposome | Irinotecan liposome intravenous infusion will be administered during the first day of treatment. |
| DRUG | SHR-1316 | SHR-1316 intravenous infusion will be administered during the first day of treatment. |
| DRUG | Fluorouracil | Fluorouracil intravenous infusion will be administered during the first day of treatment. |
Timeline
- Start date
- 2018-11-01
- Primary completion
- 2019-11-01
- Completion
- 2020-10-01
- First posted
- 2018-11-06
- Last updated
- 2018-11-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03732508. Inclusion in this directory is not an endorsement.